<DOC>
	<DOCNO>NCT01604824</DOCNO>
	<brief_summary>The purpose study assess pharmacodynamic ( PD ) effect alirocumab serum low-density lipoprotein cholesterol ( LDL-C ) patient autosomal dominant hypercholesterolemia ( ADH ) gain-of-function mutation ( GOFm ) 1 allele proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) gene loss-of-function mutation ( LOFm ) 1 allele apolipoprotein B-100 gene ( apoB ) .</brief_summary>
	<brief_title>A Study Alirocumab ( REGN727/SAR236553 ) Patients With ADH GOFm PCSK9 Gene LOFm apoB Gene</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion include , limited following : 1 . Between age 18 70 year , inclusive 2 . A history molecularly confirm PCSK9 GOFm cohort 1 history molecularly confirm PCSK9 GOFm ApoB LOFm 3 . Plasma LDLCholesterol level â‰¥70 mg/dL screen visit lipid lower therapy ( LLT ) regimen stable least 28 day Exclusion criterion include , limited following : 1 . Serum triglycerides &gt; 350 mg/dL screen visit 2 . Known positive human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus 3 . Pregnant breastfeed woman . 4 . Sexually active man woman childbearing potential unwilling practice adequate contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>